Literature DB >> 15635830

Bilateral lateral rectus resection in patients with residual esotropia.

Gyu Jin Jang1, Mi Ra Park, Soo Chul Park.   

Abstract

Unilateral or bilateral lateral rectus resection is commonly performed for the correction of residual esotropia, but few results have been reported. Twenty-eight patients with residual esotropia underwent bilateral lateral rectus (BLR) resection. Six months after operation (n = 25), there were 17 (68%) successful cases, 7 (28%) cases of undercorrection, and 1 (4%) case of overcorrection. The success rate at the 24th postoperative month (n = 11) was 72.7%. The success rate for cases of infantile esotropia (n = 18) was higher than that for acquired esotropia (n = 7) at the 6th postoperative month (p = 0.156). The results were not significantly affected by the presence of other deviations (p = 0.387), the performance of other surgery (p = 0.393), the presence of amblyopia (p = 1.00), or the amount of residual esotropia (p = 0.604). Performance of BLR resection in patients with residual esotropia after bilateral medial rectus (BMR) recession is considered appropriate due to its high success rate and provision of a stable alignment during two-year follow up.

Entities:  

Mesh:

Year:  2004        PMID: 15635830     DOI: 10.3341/kjo.2004.18.2.161

Source DB:  PubMed          Journal:  Korean J Ophthalmol        ISSN: 1011-8942


  3 in total

Review 1.  Surgical treatment for residual or recurrent strabismus.

Authors:  Tao Wang; Li-Hua Wang
Journal:  Int J Ophthalmol       Date:  2014-12-18       Impact factor: 1.779

2.  Outcomes of Bilateral Lateral Rectus Resection in Residual Esotropia following Bilateral Medial Rectus Recession.

Authors:  Reza Nabie; Vahideh Manouchehri; Sepideh Rostam Meydan
Journal:  J Curr Ophthalmol       Date:  2022-07-26

3.  Reoperation in Horizontal Strabismus and its Related Risk Factors.

Authors:  Zhale Rajavi; Mohammad Gozin; Hamideh Sabbaghi; Narges Behradfar; Bahareh Kheiri; Mohmmad Faghihi
Journal:  Med Hypothesis Discov Innov Ophthalmol       Date:  2018
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.